Banner News

Singapore, December 21, 2021 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021.


According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of correctly detecting the new Omicron strain, including B.1.1.529 BA.1 and BA.2.


Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly


Another four Variants of Concern (VOC):

Alpha variant: known as B.1.1.7

Beta variant: known as B.1.351

Gamma variant: known as P.1

Delta variant: known as B.1.617.2


Two Variants of Interest (VOI):

Lambda variant: known as C.37

Mu variant: known as B.1.621


The other six variants:

Eta variant: known as B.1.525

Iota variant: known as B.1.526

Kappa variant: known as B.1.617.1

Zeta variant: known as P.2

Epsilon variant: known as B.1.427/B.1.429

Indian variant: known as B.1.617.3

SC2 Gen2 fix border

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.